Contact Us | Print Page | Sign In | Register
Disease-Modifying Therapies
Share |


  1. A Survey of Risk Tolerance to Multiple Sclerosis Therapies
    NARCOMS, the CMSC Patient Registry, is led by a team of world-renowned MS clinicians and researchers.  Date from NARCOMS has provided the MS community with a treasure trove of new information about MS.  This article reflects outcomes of a study looking at a person’s ability to tolerate risk when considering choices of disease modifying therapy in partnership with his or her prescriber.  Kudos to the NARCOMS team for once again publishing new and exciting information.
  2. AAN Issues New Guideline on Complementary and Alternative Medicine in MS
  3. The Science of MS Management: Using Science to Select MS Therapies
  4. Thinking Critically about World Wide Web Resources (Click here)
    Esther Grassian, UCLA College Library
  5. Thinking Critically about Discipline-Based World Wide Web Resources (Click here)
    Esther Grassian, UCLA College Library

The Use of Disease-Modifying Therapies in Multiple Sclerosis: Principles and Current Evidence
A Consensus Paper by the Multiple Sclerosis Coalition, Updated on March 2017

The member organizations of the Multiple Sclerosis Coalition* have collaborated to summarize the current evidence about disease modification in multiple sclerosis (MS) and to provide support for broad access to U.S. Food and Drug Administration (FDA)-approved MS disease-modifying therapies for people. Endorsed by each of the seven MS Coalition organizations, this document serves as an evidence-based resource and reference tool for the clinical management of MS that may also be utilized in advocacy efforts to improve access to approved disease-modifying therapies for people living with MS.

*The Multiple Sclerosis Coalition (see p. 32), which was founded in 2005 to increase opportunities for cooperation and provide greater opportunity to leverage the effective use of resources for the benefit of the MS community, includes Accelerated Cure Project for Multiple Sclerosis, Can Do Multiple Sclerosis, Consortium of Multiple Sclerosis Centers, International Organization of Multiple Sclerosis Nurses, Multiple Sclerosis Association of America, Multiple Sclerosis Foundation, National Multiple Sclerosis Society and the United Spinal Association.

DMT Consensus

More InfoHide Info ]
Purpose: The purpose of this paper, which was developed by the member organizations of the Multiple Sclerosis Coalition, is to summarize current evidence about disease modification in multiple sclerosis (MS) and provide support for broad and sustained access to MS disease-modifying therapies for people with MS in the United States.
Item Name Posted By Date Posted
2019 DMT Guidelines PDF (3.78 MB) Administration 3/11/2019
DMT Consensus PDF (2.01 MB) Administration 6/15/2017
DMT_Consensus_MS_Coalition092016.pdf PDF (1.13 MB) Administration 9/8/2016
DMT_ConsensusMSC_color.pdf PDF (582.55 KB) Administration 9/8/2016
DMT_ConsensusMSC_grey.pdf PDF (569.88 KB) Administration 9/8/2016
DMT_ConsensusMSC_summary_v2.pdf PDF (786.98 KB) Administration 9/8/2016
The Consortium of Multiple Sclerosis Centers

3 University Plaza Drive, Suite 116 Hackensack, NJ 07601

Tel: 201.487.1050 | Fax: 862.772.7275